Aecom Technology (ACM) Stock Rating Reiterated at Canaccord Genuity; The $36.0 Target Indicates 5.23% Potential; Synergy Pharmaceuticals (SGYP)’s Sentiment Is 1.49

November 15, 2017 - By Maria Brooks

Among 13 analysts covering Aecom Technology (NYSE:ACM), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Aecom Technology has $48 highest and $4 lowest target. $39.17’s average target is 14.50% above currents $34.21 stock price. Aecom Technology had 37 analyst reports since August 12, 2015 according to SRatingsIntel. UBS maintained the shares of ACM in report on Monday, June 26 with “Buy” rating. The firm earned “Buy” rating on Tuesday, November 15 by Argus Research. The firm earned “Outperform” rating on Wednesday, January 4 by Robert W. Baird. As per Monday, November 23, the company rating was maintained by Argus Research. The firm earned “Buy” rating on Tuesday, August 18 by Argus Research. Canaccord Genuity maintained Aecom (NYSE:ACM) rating on Monday, June 26. Canaccord Genuity has “Hold” rating and $3600 target. KeyBanc Capital Markets maintained it with “Buy” rating and $40.0 target in Thursday, September 21 report. The firm has “Hold” rating given on Monday, March 21 by BB&T Capital. Robert W. Baird maintained the stock with “Neutral” rating in Friday, September 22 report. The stock of Aecom (NYSE:ACM) earned “Buy” rating by UBS on Tuesday, November 14.

Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The company has market cap of $456.66 million. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. It currently has negative earnings. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Great Point Partners Llc holds 5.76% of its portfolio in Synergy Pharmaceuticals Inc for 7.22 million shares. Trellus Management Company Llc owns 345,000 shares or 2.25% of their US portfolio. Moreover, Armistice Capital Llc has 1.13% invested in the company for 2.00 million shares. The New York-based Orbimed Advisors Llc has invested 0.99% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 1.20 million shares.

Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on March, 7. They expect $-0.22 EPS, up 29.03% or $0.09 from last year’s $-0.31 per share. After $-0.22 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

The stock decreased 16.80% or $0.41 during the last trading session, reaching $2.03. About 3,730 shares traded. Synergy Pharmaceuticals Inc (SGYP) has risen 24.44% since November 15, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.

Ratings analysis reveals 67% of Synergy Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Synergy Pharma, 2 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. SGYP was included in 3 notes of analysts from December 23, 2016. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Outperform” rating given on Thursday, January 5 by Oppenheimer. On Friday, December 23 the stock rating was maintained by Rodman & Renshaw with “Buy”. Citigroup downgraded the stock to “Sell” rating in Thursday, April 6 report.

Since January 1, 0001, it had 2 buys, and 0 insider sales for $43,302 activity.

AECOM is engaged in designing, building, financing and operating infrastructure assets for governments, businesses and organizations. The company has market cap of $5.36 billion. The Company’s divisions include design and consulting services , construction services (CS) and management services (MS). It has a 16.05 P/E ratio. The Company’s DCS segment is engaged in planning, consulting, architectural and engineering design services to commercial and government clients in major end markets, such as transportation, facilities, environmental, energy, water and government.

Investors sentiment increased to 1.56 in 2017 Q2. Its up 0.44, from 1.12 in 2017Q1. It increased, as 36 investors sold Aecom shares while 63 reduced holdings. 37 funds opened positions while 117 raised stakes. 126.42 million shares or 0.03% more from 126.38 million shares in 2017Q1 were reported. Noesis Mangement Corporation has 10,368 shares. Moreover, Bnp Paribas Arbitrage Sa has 0.01% invested in Aecom (NYSE:ACM). Smith Graham And Inv L P reported 136,980 shares. Primecap Mngmt Ca has invested 0.37% of its portfolio in Aecom (NYSE:ACM). Jane Street Ltd Liability Corp accumulated 16,006 shares. Envestnet Asset Mgmt Incorporated owns 30,022 shares or 0% of their US portfolio. 9,217 were reported by Los Angeles Capital And Equity Incorporated. Moreover, Private Ocean Lc has 0% invested in Aecom (NYSE:ACM) for 63 shares. Commonwealth Of Pennsylvania School Empls Retrmt Sys holds 0.01% or 22,728 shares in its portfolio. Cubist Systematic Strategies Ltd Liability owns 39,359 shares. Metropolitan Life Insur Ny has 146,562 shares. Toronto Dominion National Bank & Trust owns 60 shares. Dimensional Fund Advisors Limited Partnership has 0.07% invested in Aecom (NYSE:ACM). Ameriprise Finance has invested 0.01% in Aecom (NYSE:ACM). Fin Architects invested in 4,632 shares.

The stock decreased 3.97% or $1.42 during the last trading session, reaching $34.21. About shares traded. Aecom (NYSE:ACM) has risen 3.75% since November 15, 2016 and is uptrending. It has underperformed by 12.95% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :